Baricitinib, a rheumatoid arthritis drug, may block virus entry and reduce mortality in patients with moderate to severe Kovida-19
Such claims were made by an international scientific team under the auspices of the Karolinska Institutet in Sweden, while the results were published in the scientific journal Science Advanced.
BLACK DAY IN THE NEIGHBORHOOD! More than 100 patients have died – KORONA DOESN’T GIVE UP
ACCIDENT IN ITALY: In Milan DRAMA – a woman attacked an ambulance when she came to help a patient suffering from coronavirus?
Baricitinib, rheumatoid arthritis drug, may reduce mortality in patients with severe coronavirus
“We are pleased to report a 71% reduction in mortality in the group that received baricitinib in addition to standard care,” said Walker Lauschke, correspondent and associate professor of personalized medicine and drug development in the Department of Physiology and Pharmacology of the Carolina Institute.
“These results are particularly encouraging because the study included a large group of elderly patients, who are often excluded in other studies,” he added.
The study included 83 hospitalized patients with coronavirus pneumonia in Italy and Spain and, in addition to the usual treatment, their therapy included the use of baricitinib. Of these patients, 17% had an adverse outcome: death or breathing, compared with 35% in a control group of 83 patients who received only standard care. The mean age of the patients was 81 years.
The study included elderly patients
The researchers added that the drug had a good effect on reducing inflammation from the first day of treatment and that side effects were not recorded in any of the study participants. However, some side effects such as bacterial infections and gastrointestinal and cardiovascular complications were observed, but were also observed in the control group, so it is not clear what can be attributed to baricitinib.
“Our results show a dual anti-cytokine and antiviral effect of baricitinib and support further evaluation in the control studies,” said Ali Mirazimi, study co-author and associate professor in the Department of Laboratory Medicine at the Carolina Institute.